- Home
- SNTI vs BEAT Comparison
SNTI vs BEAT Comparison
Compare SNTI & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTI
- BEAT
- Stock Information
- Founded
- SNTI 2016
- BEAT 2015
- Country
- SNTI United States
- BEAT United States
- Employees
- SNTI N/A
- BEAT N/A
- Industry
- SNTI Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- SNTI Health Care
- BEAT Technology
- Exchange
- SNTI Nasdaq
- BEAT Nasdaq
- Market Cap
- SNTI 53.6M
- BEAT 63.5M
- IPO Year
- SNTI N/A
- BEAT 2021
- Fundamental
- Price
- SNTI $2.00
- BEAT $1.75
- Analyst Decision
- SNTI Strong Buy
- BEAT Buy
- Analyst Count
- SNTI 3
- BEAT 1
- Target Price
- SNTI $9.67
- BEAT $8.00
- AVG Volume (30 Days)
- SNTI 292.3K
- BEAT 86.8K
- Earning Date
- SNTI 11-12-2025
- BEAT 11-13-2025
- Dividend Yield
- SNTI N/A
- BEAT N/A
- EPS Growth
- SNTI N/A
- BEAT N/A
- EPS
- SNTI N/A
- BEAT N/A
- Revenue
- SNTI N/A
- BEAT N/A
- Revenue This Year
- SNTI N/A
- BEAT N/A
- Revenue Next Year
- SNTI $150.00
- BEAT $19.35
- P/E Ratio
- SNTI N/A
- BEAT N/A
- Revenue Growth
- SNTI N/A
- BEAT N/A
- 52 Week Low
- SNTI $1.26
- BEAT $0.91
- 52 Week High
- SNTI $16.94
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- SNTI 53.68
- BEAT 56.10
- Support Level
- SNTI $1.92
- BEAT $1.55
- Resistance Level
- SNTI $2.29
- BEAT $1.85
- Average True Range (ATR)
- SNTI 0.20
- BEAT 0.11
- MACD
- SNTI -0.02
- BEAT -0.00
- Stochastic Oscillator
- SNTI 26.67
- BEAT 68.75
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.